经组织分子学确认的原发性纵隔B细胞淋巴瘤中4周期后中期PET预测结局
GAINED随机3期试验的事后分析纳入138例经中心病理复核及基因表达谱和二代测序确认的原发性纵隔B细胞淋巴瘤患者,评估基于ΔSUVmax的中期PET指导治疗后的结局。中位随访39.5个月,2年无进展生存率和总生存率分别为86.2%和93.2%;多因素模型中仅大肿块和PET4的ΔSUVmax≤70%与较短无进展生存相关。
要点
- 138例确认的原发性纵隔B细胞淋巴瘤患者中,中位年龄33.5岁,55.1%为III-IV期。
- 基于ΔSUVmax的中期PET4反应是本选定临床试验人群中结局的最强预测因素。
- 多因素模型中仅大肿块和PET4的ΔSUVmax≤70%与较短无进展生存相关。
核心结论
- 基于ΔSUVmax的中期PET4反应成为该选定临床试验人群中患者结局的最强预测因素。
研究设计与样本
- GAINED研究为随机3期试验,比较奥妥珠单抗(G)与利妥昔单抗(R)联合ACVBP或CHOP14诱导后行PET指导巩固治疗。
- 本事后分析纳入620例中心复核患者中138例(22.3%)经专家病理复核及基因表达谱和二代测序确认的原发性纵隔B细胞淋巴瘤患者。
主要发现
- 中位随访39.5个月后,2年无进展生存率为86.2%,2年总生存率为93.2%。
- 多因素模型包括大肿块、aaIPI和ΔSUVmax PET2/PET4,仅大肿块与较短无进展生存相关(风险比4.39,95%CI 1.28-15.11),PET4的ΔSUVmax≤70%与较短无进展生存相关(风险比4.95,95%CI 1.71-14.3)。
- 多因素模型中上述因素均与总生存无关联。
- 有基因表达谱数据的107例中38例(35.5%)为PDL1高/PDL2高。
- 关键体细胞突变数据(n=87)包括SOCS1(70.1%)、B2M(56.3%)、STAT6(49.4%)、TNFAIP3(47.1%)、GNA13(39.1%)、CIITA(37.9%)、CD58(36.8%)和TP53(29.9%)。
关键数值与推荐
- 诱导方案为R/G-CHOP14(56.9%)和R/G-ACVBP(43.1%)。
- 根据中期PET结果,诱导后治疗包括:若第2周期后ΔSUVmax>66%且第4周期后>70%(PET2-/4-)则行标准巩固化疗(59.8%);若PET2+/4-则行强化治疗及自体移植(26.8%);若PET4+(ΔSUVmax≤70%)则行挽救治疗(13.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The GAINED study was a randomized phase 3 trial comparing obinutuzumab (G) with rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, and prednisone, combined with either vindesine or bleomycin) or CHOP14 (cyclophosphamide, doxorubicin, vincristine, and prednisone, administered on a 14-day schedule) induction, followed by positron emission tomography (PET)-guided consolidation. This post hoc analysis aimed to detail the outcomes of patients with primary mediastinal B-cell lymphoma (PMBL), verified through expert pathological review and the use of gene expression profiling (GEP) and next-generation sequencing. Of 620 centrally reviewed patients, 138 (22.3%) confirmed PMBL cases were analyzed. Baseline characteristics included a median age of 33.5 years, 63.8% female, 55.1% stage III to IV, 90.6% elevated lactate dehydrogenase, 87.6% Eastern Cooperative Oncology Group performance status score of 0 to 1, 62.3% extranodal involvement, 52.6% age-adjusted International Prognostic Index (aaIPI) of 2% to 3%, and 53.6% bulk (>10 cm). Induction regimens were R/G-CHOP14 (56.9%) and R/G-ACVBP (43.1%). Postinduction treatments, based on interim PET results, included: standard consolidation chemotherapy (59.8%) if change in maximum standardized uptake value (ΔSUVmax) of >66% after cycle 2 and >70% after cycle 4 (PET2-/4-), intensive treatment and autologous transplantation (26.8%) if PET2+/4-, and salvage therapy (13.4%) if PET4+ (ΔSUVmax of ≤70%). Among patients with GEP data (n = 107), 38 (35.5%) were PDL1high/PDL2high. Key somatic mutations data (n = 87) included SOCS1 (70.1%), B2M (56.3%), STAT6 (49.4%), TNFAIP3 (47.1%), GNA13 (39.1%), CIITA (37.9%), CD58 (36.8%), and TP53 (29.9%). After a median follow-up of 39.5 months, 2-year progression-free survival (PFS) and overall survival (OS) rates were 86.2% and 93.2%, respectively. In a multivariate model including bulk, aaIPI, and ΔSUVmax PET2/PET4, only bulk and ΔSUVmax PET4 of ≤70% were associated with shorter PFS (hazard ratio, 4.39 [95% confidence interval (CI), 1.28-15.11] and 4.95 [95% CI, 1.71-14.3], respectively), whereas none were associated with OS. The ΔSUVmax-based interim PET4 response emerged as the strongest predictor of patient outcomes in this selected clinical trial population. This trial was registered at www.ClinicalTrials.gov as #NCT01659099.
引用
- Camus V, Molina T, Desmots F, et al. Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma. Blood Adv. 2025. PMID: 40030008. doi:10.1182/bloodadvances.2024015577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。